Accelerated suppression of primary EBV infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.

Publication Type:

Journal Article


Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014)


2014, Center-Authored Paper, Clinical Research Division, March 2014, Public Health Sciences Division, Vaccine and Infectious Disease Division


We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan HIV-infected infants starting nevirapine- versus lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.